Vimian Group

Vimian’s Diagnostics segment supplies PCR and ELISA solutions for disease identification and eradication in livestock and companion animals.

Vimian’s MedTech segment provides orthopedic products for companion animals, including fracture plates and hip replacement systems, sold to clinics, hospitals, and universities in the United States, Europe, and APAC.

Vimian’s Specialty Pharma segment enjoys a strong global position within veterinary allergy, dermatology, otology and specialised nutrition.

Vimian’s Veterinary Services segment offers clinics procurement, education, and digital tools to improve operations, growth, and profitability.

Vimian Group has been upgraded by MSCI to an ‘AAA’ ESG rating, the highest rating available, placing Vimian among the top 19% of MSCI-rated companies globally and as a leader among 153 Health Care Equipment & Supplies companies.

Search job openings across the Vimian network.

Vimian operates globally in animal health, covering specialty pharma, MedTech, veterinary services, and diagnostics. The company connects pioneering businesses to expand access to innovative solutions for animal health professionals and pet owners.

Vimian partners with entrepreneurs and management teams in animal health niches to drive innovation and growth.

Vimian and its companies drive innovation and leadership in animal health categories.

Vimian supports veterinarians, animal health professionals, and pet owners in treating more animals more effectively.

Vimian invites inquiries from entrepreneurs, innovators, and business owners interested in improving animal health.

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services.

Vimian uses cookies in order for the website to work more effectively and in order for Vimian to obtain information concerning who visits the website.

Vimian Group AB (publ) with registration number 559234-8923 (“Vimian”) is a global group of innovation-driven companies with a shared passion for making a positive impact through improving animal health. The information and provisions set forth below apply in respect of Vimian’s website.

Vimian Group AB and its subsidiaries uphold high ethical standards in business conduct, providing guidance on ethical dilemmas.

Vimian Group AB and subsidiaries Nextmune, Movora, Indical Bioscience, and VetFamily offer a whistleblowing platform to address suspected wrongdoings.

Vimian Group AB invites institutional investors, analysts, and financial media to its **Capital Markets Day** in Stockholm on **24 November 2026**. The event will feature presentations, with a live webcast available for remote attendees.

Oct 2026vimian.comNews article

Vimian reports **15% total revenue growth to EUR 120.3 million** in Q3 2026, driven by **11% organic growth**. The company outperforms the broader animal health market through targeted niche focus, a strong brand portfolio, and disciplined execution in its entrepreneurial structure.

Oct 2026vimian.comNews article

Vimian Group AB acquires Norfolk Medical Products, a US-based supplier of implants and consumables for veterinary soft tissue surgery. The deal strengthens Vimian’s position in the veterinary surgical market. Norfolk reported approximately **$6.9 million** in annual revenue for the period ending August 2026.

Oct 2026vimian.comNews article

Vimian Group AB issued D shares, E1 2026 shares, and E2 2026 shares in September under its **LTIP 2026/2029 incentive program**, increasing its total shares and voting rights. The move aligns with the company’s long-term equity compensation strategy for employees and stakeholders. No additional details on volume or allocation were disclosed.

Sep 2026vimian.comNews article